The Science, The Trial, and What It Means for the Future of Human Teeth
In October 2024, Kyoto University Hospital began injecting humans with a drug designed to grow entirely new teeth from scratch. Not implants. Not prosthetics. Not veneers glued onto stumps. Actual biological teeth, generated by the body's own dormant cellular machinery, triggered by a single antibody injection into the gums.
The drug is called TRG-035. It is a humanized monoclonal antibody that blocks a protein called USAG-1, a molecular brake that has been keeping a hidden third set of tooth buds locked inside your jaw for your entire life. Shut off that brake, and the buds wake up.
This is not theoretical. It already worked in mice, ferrets, and dogs. Now 30 men in Kyoto are the first humans to test whether the same mechanism translates to our species. If Phase I clears safety, the next trial targets children born without teeth. The team behind it is aiming for public availability around 2030.
The implications reach beyond dentistry. If the body can be chemically instructed to reactivate a dormant developmental program, a process it already knows how to execute but has been suppressing, the same principle could eventually apply to other tissues and organs that currently cannot regenerate. Tooth regeneration is a proof of concept for a much larger idea: that biological regeneration is not absent in humans, but suppressed, and that targeted molecular interventions can lift that suppression.
That timeline is not decades away. It is four years.
This guide breaks down every layer of the science: the protein, the antibody, the preclinical evidence, the clinical trial design, the economic disruption potential, the skepticism, and what it structurally means for dentistry, aging, and regenerative medicine. It is written for the pattern-minded reader who wants to understand the mechanisms, not just the headlines.
Written by Yuma Heymans (@yumahey), founder of O-mega, who has been tracking how biological and artificial intelligence converge to reshape industries from healthcare to enterprise automation.
Contents
- The Biological Foundation: Why Humans Have a Hidden Third Set of Teeth
- USAG-1: The Protein That Keeps Your Teeth Locked
- How the Antibody Works: Selective BMP Restoration
- Preclinical Evidence: Mice, Ferrets, and Dogs
- The Clinical Trial: Design, Participants, and Timeline
- Toregem BioPharma: The Startup Behind the Drug
- Phase 2 and Beyond: Children With Congenital Anodontia
- Japan's Dental Health Crisis and the 8020 Movement
- The Economic Disruption: Implants, Dentures, and a $14 Billion Market
- Competing Approaches: How Other Teams Are Trying to Regrow Teeth
- The Skepticism: What Could Go Wrong
- Where AI Meets Regenerative Dentistry
- What This Means for the Future of Aging
1. The Biological Foundation: Why Humans Have a Hidden Third Set of Teeth
The headline that grabs attention ("Japan is growing new teeth in humans") rests on a biological fact that most people have never heard: humans carry dormant tooth buds inside their jawbones. These are not metaphorical. They are real epithelial structures, remnants of a developmental program that begins during embryonic growth and then gets shut down before it can complete.
To understand why this matters, you need to understand how teeth form in the first place. Every tooth you have ever grown started as a thickening of the oral epithelium, a band of tissue called the dental lamina. This lamina buds off tooth germs in two waves. The first wave produces your 20 deciduous (baby) teeth. The second wave produces your 32 permanent teeth. But there is a third wave, a vestigial echo, that begins to form and then self-destructs through a process called apoptosis, which is programmed cell death.
This third wave is not fiction. A 2019 paper by Kiso, Takahashi, and colleagues published in the Journal of Dental Research demonstrated that the third dentition is the primary cause of supernumerary tooth formation in the premolar region - Journal of Dental Research. When something goes wrong with the apoptotic signal, a person grows extra teeth. Roughly 1 in 3 cases of hyperdontia (the condition of having too many teeth) results from these third-wave buds escaping their programmed death and developing into actual teeth.
The evolutionary logic is straightforward. Many vertebrates replace teeth continuously throughout their lives. Sharks cycle through thousands. Crocodiles regrow lost teeth repeatedly. Even some mammals, like manatees, have a form of continuous tooth replacement. Humans lost this ability at some point in our evolutionary history, but the genetic infrastructure did not disappear entirely. It got silenced. The molecular machinery for a third set of teeth still exists in your genome. It is simply being actively suppressed.
The implications extend beyond a curiosity of developmental biology. If humans truly carry the genetic instructions and the physical precursor structures for a third set of teeth, then tooth loss is not an irreversible biological endpoint. It is a condition maintained by active molecular suppression. The difference between "your body cannot grow new teeth" and "your body is being prevented from growing new teeth" is the difference between an engineering impossibility and an engineering challenge. One requires building something from nothing. The other requires removing a barrier.
This reframing is what made the research program possible. Dr. Katsu Takahashi, now CTO of Toregem BioPharma, has been studying tooth development since the early 1990s at Kyoto University. His career trajectory tracks the evolution of this understanding: from cataloguing the genetic players involved in odontogenesis (tooth formation) to identifying which ones act as suppressors, to designing a therapeutic intervention that targets the most critical suppressor.
The evolutionary perspective also explains why the drug works across species. The third dentition phenomenon is not unique to humans. It is a conserved feature of mammalian biology, a remnant of the more robust tooth-replacement systems that ancestral mammals possessed. Ferrets, which are diphyodont like humans, also have vestigial third-dentition structures. So do dogs. The USAG-1 suppression mechanism is conserved because the developmental program it suppresses is conserved. This cross-species conservation is what gave the research team confidence to move from mice to ferrets to dogs to humans, each step validating that the same molecular logic applies.
The suppression mechanism centers on a single protein. And that protein became the target of a drug.
2. USAG-1: The Protein That Keeps Your Teeth Locked
The protein is called USAG-1, which stands for Uterine Sensitization Associated Gene-1. It is also known by several other names in the literature: SOSTDC1 (Sclerostin Domain Containing 1), ectodin, and WISE (Wnt Modulator in Surface Ectoderm). The multiple names reflect the fact that different research groups discovered it independently in different tissue contexts before realizing they were looking at the same molecule.
USAG-1 is what biologists call a bifunctional antagonist. It simultaneously blocks two of the most important signaling pathways in developmental biology: BMP (Bone Morphogenetic Protein) signaling and Wnt signaling. Both of these pathways are essential for tooth development. BMP signaling drives the differentiation of cells into the specialized tissues that make up a tooth (enamel, dentin, pulp, cementum). Wnt signaling controls cell proliferation, the expansion of progenitor populations that build the tooth structure.
When USAG-1 is present, it binds to BMP ligands (specifically BMP2, BMP4, and BMP7) and to Wnt co-receptors (LRP5 and LRP6), preventing both signals from reaching their target cells. This creates a double lock on tooth development. The dormant third-dentition buds cannot differentiate (because BMP is blocked) and cannot proliferate (because Wnt is suppressed). The buds undergo apoptosis and disappear.
Single-cell RNA sequencing has mapped exactly where USAG-1 is expressed in the oral cavity. It is produced by specific gingival fibroblast subsets: CD9+ APCDD1+ fibroblasts (making up about 45-50% of expressing cells) and CDH19+ LAMA2+ fibroblasts (about 30-35%). Approximately 60% of basal epithelial cells in the gums also express USAG-1 - PMC. This means the suppression is not coming from one cell type. It is a distributed signal across multiple tissue populations, creating a robust barrier against accidental tooth formation.
The critical insight that made the drug possible came from understanding that USAG-1's two functions (BMP blocking and Wnt blocking) operate through different binding surfaces on the protein. The BMP-binding site and the LRP5/6-binding site are physically separate. This meant it was theoretically possible to design an antibody that blocks one interaction without blocking the other.
That distinction turned out to be the key to everything.
3. How the Antibody Works: Selective BMP Restoration
Dr. Katsu Takahashi's team at the Medical Research Institute Kitano Hospital in Osaka did not simply knock out USAG-1 entirely. That would have been the brute-force approach, and it would have been dangerous. USAG-1 modulates both BMP and Wnt pathways, and Wnt signaling is involved in cell proliferation across many tissues. Removing all USAG-1 function could theoretically trigger uncontrolled cell growth, not just in teeth but in bone, kidney, and other organs where USAG-1 is expressed.
Instead, the team generated five different monoclonal antibodies (clones #12, #16, #37, #48, and #57), each binding to a different part of the USAG-1 protein surface. They then characterized which pathway each antibody blocked - Science Advances.
The results split cleanly into three categories. Antibodies #37 and #12 blocked USAG-1's binding to BMP proteins but left the Wnt interaction intact. Antibodies #16 and #48 blocked Wnt binding but left BMP alone. Antibody #57 blocked both.
Clone #37 turned out to be the winner. By blocking only the BMP interaction, it restored the differentiation signals that tooth buds need to develop into actual teeth, while leaving Wnt modulation intact. This meant cell proliferation remained regulated. Teeth could grow, but the growth was controlled.
Epitope mapping revealed why this selectivity works at a structural level. Antibody #37 binds to "a surface-exposed edge strand of the central beta-sheet of USAG-1," a region that is physically distinct from the surface where USAG-1 contacts LRP5/6. The antibody essentially covers one lock while leaving the other untouched.
This is not a trivial engineering achievement. Most therapeutic antibodies work by simply neutralizing their target completely. Designing one that selectively blocks one function of a bifunctional protein while preserving another requires detailed structural knowledge and careful screening. It is the kind of precision that separates a viable drug candidate from a laboratory curiosity.
To appreciate the difficulty, consider the protein engineering challenge. USAG-1 is a relatively small protein, and its functional surfaces are close together in three-dimensional space. Generating an antibody that binds tightly enough to block one surface while having zero affinity for an adjacent surface requires either extraordinary luck in initial screening or sophisticated computational modeling to guide the selection. The Takahashi team used a combination of both: generating a library of monoclonal antibodies through standard hybridoma technology, then systematically characterizing each one's binding properties using surface plasmon resonance and competitive binding assays. Out of five candidates, only two (clones #37 and #12) showed the desired BMP-selective profile.
The dose-response data from the subsequent animal studies confirmed that clone #37's selectivity translated into functional outcomes. At the appropriate dosage, BMP signaling was restored sufficiently to trigger tooth bud activation, while Wnt-mediated proliferation remained within normal bounds. This therapeutic window, the range between "enough drug to grow a tooth" and "too much drug causing uncontrolled growth," is what Phase I is designed to define in humans.
The approach is also elegant from a safety perspective. Rather than introducing foreign cells, genetic material, or synthetic scaffolds into the jaw, the drug simply removes one molecular brake on a process the body already knows how to execute. The tooth-building program is already coded into your DNA. The cells that execute it are already present in your gums. The only thing missing is the signal to start. TRG-035 provides that signal by removing the protein that says "don't."
4. Preclinical Evidence: Mice, Ferrets, and Dogs
The preclinical data spans nearly two decades of work, beginning with a 2007 discovery and culminating in the landmark 2021 Science Advances paper that directly led to the human trial.
The 2007 Foundation
The story begins with a straightforward genetic experiment. Takahashi's group created USAG-1 knockout mice, animals genetically engineered to produce no USAG-1 at all. The result was immediate and dramatic: the mice developed supernumerary teeth. Specifically, rudimentary incisor tooth buds that would normally undergo apoptosis instead survived and erupted as fully formed extra teeth - PubMed.
This was the proof of concept. Remove USAG-1, and dormant tooth buds develop. But a genetic knockout is not a drug. You cannot delete a gene from an adult human's genome as a dental treatment (at least not with current technology, and not without raising severe safety and regulatory questions). The team needed a way to temporarily and locally suppress USAG-1 function. That is what led to the antibody approach.
The 2021 Landmark Study
The Science Advances paper published in February 2021 is the single most important publication in this field. It demonstrated that a monoclonal antibody (clone #37) could achieve the same tooth-regenerating effect as a genetic knockout, but in a targeted, temporary, and dose-dependent manner - PMC.
The mouse experiments were precise. Pregnant mice carrying the EDA1 mutation (which causes reduced tooth number, mimicking human hypodontia) were injected intraperitoneally with anti-USAG-1 antibodies at a dose of 16 micrograms per gram of body weight at embryonic day 13. Antibody #37 rescued molar hypodontia in a dose-dependent manner, meaning higher doses produced more reliable tooth formation. Functional tooth regeneration was achieved in 100% of treated mice, with the regenerated teeth showing normal enamel and dentin architecture.
The team also crossed USAG-1 knockout mice with MSX1 knockout mice (MSX1 being another gene involved in tooth development) to understand genetic interactions. The double-knockout was so lethal that only 3 of 151 littermates achieved the target genotype, underscoring how fundamental these pathways are to development. The surviving animals showed a range of dental phenotypes: normal teeth, extra teeth, and fused mandibular molars.
Additionally, the paper analyzed 78 human patients with supernumerary teeth to understand natural patterns of third dentition activation in humans, providing a direct bridge between the animal model and human biology.
The Ferret Model
Mice are useful but imperfect models for human dentistry. Mice are monophyodont: they grow only one set of teeth. Humans are diphyodont: two sets (baby teeth, then permanent teeth). To test the antibody in a more human-like dental system, the team turned to ferrets, which are also diphyodont.
The ferret experiments required significantly more aggressive dosing. Where mice needed 16 micrograms per gram, ferrets required 80 micrograms per gram, a fivefold increase. They also needed three separate administrations of the antibody, plus immunosuppression to prevent rejection of the humanized antibody.
Despite these higher requirements, the results were positive. Ferrets treated with antibody #37 developed supernumerary teeth in the maxillary incisor region. The regenerated teeth had complete internal structures: enamel, dentin, and pulp, all organized in the correct architectural pattern.
The team also demonstrated tooth regeneration in a beagle dog, adding another diphyodont species to the evidence base.
An additional study published in Scientific Reports (2021) explored an alternative delivery mechanism: siRNA (small interfering RNA) that directly silences USAG-1 gene expression rather than blocking the protein with an antibody. When applied topically to Runx2-deficient mice (which have impaired bone and tooth development), the siRNA promoted tooth regeneration. However, the approach achieved only approximately 50% USAG-1 mRNA inhibition in vitro, compared to the near-complete protein blockade achieved by the monoclonal antibody - Nature. This suggests that the antibody approach may be more effective than genetic silencing for clinical applications, though siRNA-based delivery could eventually offer advantages for local, sustained treatment.
The progression from mice to ferrets to dogs to humans follows the standard drug development pathway, but the consistency of results across species is noteworthy. In every diphyodont species tested, blocking USAG-1 activated dormant tooth buds. This cross-species conservation suggests that the mechanism is deeply embedded in mammalian biology, not a quirk of one animal model.
5. The Clinical Trial: Design, Participants, and Timeline
The human clinical trial represents the culmination of nearly 20 years of research. It received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on March 25, 2024, and enrollment began at Kyoto University Hospital on October 18, 2024 - Toregem BioPharma.
Trial Design
This is a Phase I trial, meaning its primary objective is safety, not efficacy. The study is not trying to prove that TRG-035 grows teeth in humans (though the team will obviously be watching for that). It is trying to answer three specific questions.
First, is a single dose of TRG-035 safe in healthy adult humans? The antibody is injected directly into the gums at the site of a missing tooth. Any systemic effects (particularly in kidney and bone, where USAG-1 is also expressed) need to be monitored and characterized.
Second, if tooth regeneration does occur, how do the newly grown teeth integrate with surrounding tissues? A tooth that grows but does not anchor properly into the periodontal ligament or does not form proper root structure would be clinically useless.
Third, what is the durability of any regenerated teeth? Do they persist, or does the body eventually resorb them once the antibody clears?
Participants
The trial enrolled 30 healthy adult males aged 30 to 64, each missing at least one molar tooth. The restriction to males is standard for Phase I trials of novel biologics, as it eliminates pregnancy-related confounding variables. The age range captures a population where tooth loss is common enough to provide missing-tooth sites but young enough to have robust healing capacity.
Each participant receives a single injection of TRG-035 into the gum tissue at the site of a missing tooth. The trial is dose-escalating, meaning different groups receive different concentrations to identify the optimal dosage window.
Collaborating Institutions
The trial is a multi-institutional effort involving Kyoto University Hospital (Department of Early Medical Development), Ki-CONNECT (Research Centre for Next-Generation Medicine and iPS Cell Therapy), Kitano Hospital, Toregem BioPharma, and AMED (Japan Agency for Medical Research and Development) - France 24.
What "Safety" Means in This Context
Phase I safety assessment for a tooth regeneration antibody is more nuanced than for a typical therapeutic. The standard Phase I checklist (adverse events, lab abnormalities, vital signs, immunogenicity) applies, but the dental-specific endpoints are what make this trial unique.
The team needs to monitor whether any tooth-like structures begin forming at the injection site, and if so, whether they form correctly. A malformed tooth bud that partially erupts and then stalls would be worse than no response at all, because it could damage surrounding bone or adjacent teeth. The trial will track radiographic imaging of the jaw over the full 11-month period to detect any structural changes, even subclinical ones.
They also need to monitor USAG-1 levels systemically. Although the injection is local (into the gum tissue), some antibody will inevitably enter the bloodstream. Since USAG-1 is expressed in kidney and bone, the safety evaluation must include renal function markers and bone density measurements. The hope is that local injection concentrates the drug at the target site while keeping systemic levels below the threshold for off-target effects. But this is precisely what the trial needs to confirm.
Timeline
The Phase I trial has an estimated duration of 11 months, running through 2025. Results are expected to inform the design of Phase II, which will shift the target population from healthy adults to children with congenital tooth agenesis.
6. Toregem BioPharma: The Startup Behind the Drug
The commercial entity translating this research into a product is Toregem BioPharma Co., Ltd., a Kyoto University spinoff founded in May 2020. The name "Toregem" is a portmanteau of "tooth regeneration medicine."
The leadership team reflects the academic origins of the project. Dr. Katsu Takahashi serves as Chief Technology Officer, bringing his three decades of research directly into the company. Honoka Kiso (Dentist, MD, Ph.D.) serves as CEO, handling the regulatory and business strategy. Muneo Takatani (Pharmacist, Ph.D.) is Chief Business Officer, managing partnerships and manufacturing.
Funding
Toregem raised approximately 1.5 billion yen (roughly $10 million USD) in a Series B round completed on August 30, 2024. Investors included Tohoku University Venture Partners, JIC Venture Growth Investments, Astellas Venture Management (the venture arm of Astellas Pharma, one of Japan's largest pharmaceutical companies), and eight other investors - Toregem BioPharma.
The involvement of Astellas Venture Management is significant. Astellas is a major pharmaceutical company with deep expertise in biologics manufacturing and global regulatory pathways. Their investment signals that a serious pharma player sees commercial viability in this approach.
Additionally, AMED selected TRG-035 for the FY 2024 Venture Ecosystem Enhancement Project for Drug Discovery in June 2024, providing government-backed funding and support for the clinical development program.
Manufacturing
Toregem signed a Memorandum of Understanding with WuXi Biologics in October 2022 for CMC (Chemistry, Manufacturing, and Controls) services. This covers cell line development, cell banking, cell culture development, biologics GMP manufacturing, and bioassay development - PR Newswire. WuXi Biologics is one of the world's largest contract development and manufacturing organizations (CDMOs) for biologics, with the infrastructure to scale antibody production from clinical to commercial volumes.
This partnership matters because manufacturing monoclonal antibodies at scale is one of the most common bottlenecks in biotech. Many promising drugs fail not because the science is wrong but because the manufacturing is too expensive or unreliable. Having WuXi onboard from an early stage de-risks this element of the commercialization pathway.
7. Phase 2 and Beyond: Children With Congenital Anodontia
If Phase I demonstrates safety, the next target population is not the general adult market. It is children with congenital tooth agenesis, a group of genetic conditions where individuals are born without some or all of their permanent teeth.
The strategic logic is clear. Congenital anodontia is a well-defined condition with a clear unmet medical need, no existing curative treatment, and a patient population (children) where the biological potential for tooth growth is at its highest. It is also a path to orphan drug designation, which provides regulatory fast-tracking, tax incentives, and market exclusivity.
Regulatory Milestones Already Achieved
Toregem has been executing this strategy with precision. On September 29, 2025, TRG-035 was designated an Orphan Medicinal Product by Japan's Ministry of Health, Labour and Welfare for severe congenital oligodontia (defined as 6 or more missing permanent teeth) - Toregem BioPharma. This designation grants tax incentives, financial aid, reduced regulatory fees, and priority review.
On November 27, 2025, Toregem received an official response from the U.S. FDA regarding a pre-IND (Investigational New Drug) meeting for TRG-035 - Toregem BioPharma. This signals that Toregem is not limiting its ambitions to Japan. They are laying the groundwork for U.S. clinical trials.
In February 2026, the AMED Stage Gate review was passed, accelerating Phase 2 planning.
Target Population
The Phase 2 target is children aged 2 to 7 with severe congenital oligodontia. The prevalence data provides context for the scale of this condition.
Hypodontia (missing 1-5 teeth, excluding wisdom teeth) affects 3-10% of the general population. Oligodontia (missing 6 or more teeth) is rarer, affecting 0.1-0.5% of the population. Complete anodontia (no teeth at all) is extremely rare. Across European and Asian populations, congenital tooth agenesis in any form affects 3-11% of individuals, with the highest prevalence recorded in Africa at 13.4% and the lowest in Latin America at 4.4% - NCBI GeneReviews.
For children with severe oligodontia, the current standard of care involves dentures, dental implants (usually delayed until skeletal maturity around age 18), and extensive orthodontic work. None of these replace biological teeth. If TRG-035 can stimulate tooth growth in these children, it would be the first curative treatment for a condition that currently requires decades of prosthetic management.
Projected Development Timeline
Based on Toregem's public communications and regulatory milestones, the projected timeline looks like this:
- Phase I (adult safety): 2024-2025
- Phase II (efficacy in children): Late 2026 through 2027
- Phase III (large-scale trials): Through 2029
- Commercialization: Approximately 2030
This is an aggressive but not unreasonable timeline, particularly given the orphan drug pathway, which compresses regulatory review periods.
The strategic significance of the FDA engagement deserves emphasis. Japan's PMDA is a respected regulatory agency, but FDA approval would open the world's largest pharmaceutical market. The U.S. dental implant market alone is estimated at over $2 billion, and American patients typically pay the highest prices globally for dental procedures. If TRG-035 achieves FDA approval for congenital anodontia, the path to broader indications (age-related tooth loss, trauma-related tooth loss) in the U.S. market would be substantially easier, as the safety and manufacturing data from the orphan indication would carry over.
The orphan drug economics also provide a financial runway for Toregem. Orphan drug designation in both Japan and the U.S. comes with market exclusivity periods (typically 7-10 years), during which generic or biosimilar competitors cannot enter. For a small biotech company with $10 million in Series B funding, this exclusivity is essential. It guarantees a protected revenue stream from the initial indication, funding the larger clinical trials needed to expand into the mass market for age-related tooth loss.
The global prevalence data also reveals an underappreciated dimension of the market opportunity. While oligodontia (6+ missing teeth) affects only 0.1-0.5% of the population, milder hypodontia (1-5 missing teeth, excluding wisdom teeth) affects 3-10%. That means somewhere between 240 million and 800 million people worldwide are missing at least one permanent tooth due to congenital factors alone, before counting age-related or trauma-related tooth loss. Even capturing a small fraction of this population represents a massive addressable market.
8. Japan's Dental Health Crisis and the 8020 Movement
Japan's interest in tooth regeneration is not academic. It reflects a national dental health challenge that has been a public health priority for over three decades.
In 1991, Japan's Ministry of Health, Labour and Welfare and the Japanese Dental Association launched the 8020 Movement, a public health campaign with a specific goal: ensure that every Japanese citizen retains at least 20 natural teeth by age 80. The threshold of 20 teeth is not arbitrary. Research demonstrates that a person with 20 or more teeth can eat almost all foodstuffs without difficulty, maintaining nutritional intake and quality of life - PMC.
The campaign has been remarkably successful by its own metrics. In 2005, only 25.0% of 80-year-olds had 20 or more natural teeth. By 2016, that figure had risen to 51.2%, surpassing the 50% target that had been set for 2022. The improvement is attributed to better preventive care, fluoridation, dietary guidance, and regular dental check-ups.
But the aggregate numbers mask a stubborn structural problem. Among Japanese adults aged 65 and older, the distribution of remaining teeth reveals deep disparities. 34.2% have 20 or more teeth (the healthy threshold). 27.1% have 10-19 teeth (functional but compromised). 26.3% have 1-9 teeth (severely compromised). And 12.4% are completely edentulous, meaning they have zero natural teeth - BMC Geriatrics.
A longitudinal study tracking tooth loss across Japan from 2007 to 2017 showed consistent improvement: mean missing teeth (age-adjusted) declined from 6.80 in 2007 to 6.01 in 2012 to 4.99 in 2017 - PMC. The trend is positive, but even at this rate of improvement, millions of elderly Japanese will continue to lose teeth for decades.
Japan also has the world's oldest population. 29.3% of Japanese citizens are aged 65 or older. The combination of extreme longevity and age-related tooth loss creates a massive population of people living with compromised dental function. Tooth loss is not just a cosmetic issue. Research has consistently linked it to malnutrition (inability to chew fibrous foods), cognitive decline (reduced sensory input from the oral cavity correlates with brain atrophy), and increased mortality risk - Scientific Reports.
The connection between tooth loss and systemic health is one of the most underappreciated findings in geriatric medicine. The oral cavity is not an isolated system. It is the entry point for nutrition, a major source of chronic inflammation (via periodontal disease), and a sensory organ whose stimulation affects brain function. When teeth are lost, all three of these functions degrade simultaneously.
Nutritional impact is the most immediately measurable. Individuals with fewer than 20 teeth show significantly reduced intake of fiber, fresh vegetables, and lean proteins, precisely the nutrient categories that protect against cardiovascular disease, diabetes, and sarcopenia (age-related muscle loss). They compensate by shifting toward softer, calorie-dense, nutrient-poor foods: processed carbohydrates, soft sweets, and liquids. This dietary shift alone can accelerate metabolic decline.
The cognitive connection is more subtle but equally well-documented. Each tooth root is surrounded by periodontal ligament fibers containing mechanoreceptors that send proprioceptive signals to the brain during chewing. These signals stimulate blood flow in the hippocampus and prefrontal cortex. When teeth are lost and replaced with dentures (which have no periodontal ligament), this proprioceptive feedback disappears. Several large longitudinal studies have found that every additional lost tooth is associated with a measurable increase in dementia risk, even after controlling for socioeconomic status, smoking, and other confounders.
The inflammatory pathway operates through a different mechanism. Tooth loss is frequently preceded by periodontal disease, a chronic bacterial infection of the gums that produces systemic inflammation. Even after teeth are extracted, residual gum inflammation can persist. The resulting chronic low-grade inflammation (measured by C-reactive protein and IL-6 levels) is now recognized as a contributor to atherosclerosis, insulin resistance, and neurodegeneration. Regenerating natural teeth could theoretically restore the periodontal ligament, reduce inflammation, and break this cycle.
In this context, a drug that could reverse tooth loss is not a convenience. It is a public health intervention with implications for nutrition, cognition, and lifespan in one of the world's fastest-aging societies.
The steady upward trajectory shows the impact of preventive dentistry. But prevention has a ceiling. It cannot regrow teeth that are already lost. That is the gap TRG-035 aims to fill.
9. The Economic Disruption: Implants, Dentures, and a $14 Billion Market
The economic implications of a tooth regeneration drug extend far beyond one startup's revenue. Two entire industries, dental implants and dentures, exist primarily because humans cannot regrow lost teeth. If that changes, the downstream effects ripple through dental practices, medical device companies, insurance models, and healthcare spending worldwide.
The Dental Implant Market
The global dental implant market was valued at approximately $5.56 billion in 2025, according to Grand View Research, with projections reaching $11.02 billion by 2033 at a compound annual growth rate (CAGR) of 7.3% - Grand View Research. Other estimates place the market even larger, with SkyQuest valuing it at $11.76 billion in 2025 and projecting $15.08 billion by 2032 at a CAGR of 9.02%.
A single dental implant costs between $3,000 and $6,000 in the United States, and a full-mouth restoration can exceed $50,000. These prices reflect the complexity of the procedure: titanium posts are surgically anchored into the jawbone, custom abutments are fitted, and ceramic crowns are fabricated and attached. The process takes months and often requires bone grafting if the jaw has atrophied from prolonged tooth loss.
Major companies in this space include Straumann (Switzerland), Dentsply Sirona (USA), Zimmer Biomet (USA), Nobel Biocare (owned by Envista), and Osstem Implant (South Korea). These companies have built multi-billion-dollar businesses on the premise that lost teeth must be replaced mechanically.
The Denture Market
The global denture market is smaller but still substantial, valued at approximately $2.43 billion in 2025 and projected to reach $3.36-4.35 billion by 2030-2034 at a CAGR of about 6.6% - Fortune Business Insights. Dentures are the most common solution for severe tooth loss, particularly among elderly populations in countries where implants are unaffordable or medically contraindicated.
Combined Disruption Potential
Together, these markets represent roughly $8-14 billion annually in global spending on replacing lost teeth with mechanical or prosthetic substitutes. If TRG-035 or a successor drug can reliably regenerate natural teeth, a portion of this spending shifts from prosthetic manufacturing to pharmaceutical treatment.
The disruption would not be immediate or total. Even optimistic timelines put broad commercialization at 2030 at the earliest, and initial availability will almost certainly be limited to the orphan indication (congenital anodontia). Expansion to age-related tooth loss would require additional clinical trials and regulatory approvals. And the drug requires existing dormant tooth buds, which may not be present at every missing-tooth site in every patient.
But the structural economics favor the biological approach. Growing a natural tooth from existing cellular machinery is fundamentally less resource-intensive than manufacturing a titanium implant, surgically installing it, and fitting a custom crown. If the drug works at scale, the per-tooth cost should be dramatically lower than current implant procedures, even accounting for pharmaceutical pricing markups.
The pricing dynamics of tooth regeneration deserve closer examination. Monoclonal antibody therapies are not cheap. Current antibody drugs in other therapeutic areas (oncology, autoimmune disease, rare disease) typically cost between $10,000 and $100,000 per treatment course. However, the cost structure of a tooth regeneration antibody would differ from chronic-use antibodies in a critical way: it would likely be a single injection per tooth, not an ongoing treatment. The body does not need continuous suppression of USAG-1 to grow a tooth. It needs a temporary window in which the suppression is lifted, and the tooth bud activates. Once the tooth has begun developing, the process is self-sustaining.
This single-dose economics dramatically changes the value equation. Compare a single injection (even at $5,000-$15,000 per tooth) against the current all-in cost of a dental implant ($3,000-$6,000 for the implant, plus $1,500-$3,000 for the abutment and crown, plus potential bone grafting at $500-$3,000, plus multiple surgical visits over 4-6 months). A biological tooth that anchors itself, forms its own root, and maintains itself through normal biological processes eliminates the ongoing maintenance costs of prosthetics: no crown replacements, no implant screw loosening, no denture relining.
The insurance implications are equally significant. Dental insurance in most countries covers a fraction of implant costs, leaving patients with substantial out-of-pocket expenses. A pharmaceutical treatment for tooth loss could shift the reimbursement model from dental insurance (which typically has low annual caps) to medical insurance (which covers prescribed drug therapies), potentially improving access for lower-income patients.
The parallel to other biological disruptions is instructive. When statins replaced surgical interventions as the first-line treatment for cardiovascular risk, the shift did not eliminate cardiology. It restructured the entire field around pharmaceutical management rather than surgical intervention. A similar shift could occur in dentistry, where the emphasis moves from mechanical replacement to biological regeneration.
The workforce implications for the dental profession should not be overlooked either. Implantology is one of the highest-revenue specializations in dentistry. If demand for implants declines, the economic model of dental practices that depend on implant revenue will need to adapt. Conversely, a new category of "regenerative dentistry" would emerge, requiring new training, new diagnostic capabilities (imaging to assess dormant tooth bud status), and new clinical protocols. The net effect on the dental profession could be neutral in terms of total economic activity but transformative in terms of what dentists actually do.
The implant market alone dwarfs the current funding of tooth regeneration research. A successful drug would redirect a significant portion of that spending.
10. Competing Approaches: How Other Teams Are Trying to Regrow Teeth
TRG-035 is the most clinically advanced tooth regeneration approach, but it is not the only one. Several other research programs are attacking the same problem from different angles. Understanding the competitive landscape reveals why the anti-USAG-1 antibody has emerged as the frontrunner.
Tooth Germ-Derived Stem Cells (TGSC)
Multiple research groups are attempting to grow teeth from stem cells derived from extracted tooth germs. The approach involves harvesting dental pulp stem cells, seeding them onto bioengineered scaffolds with controlled porosity, and combining them with angiogenic co-cultures to provide blood supply. The goal is to create a bioengineered tooth that can be implanted into the jaw.
The fundamental challenge is morphological fidelity. A natural tooth has an incredibly precise architecture: enamel (the hardest substance in the human body) layered over dentin, surrounding a pulp chamber with nerves and blood vessels, anchored by cementum and periodontal ligament fibers. No stem cell approach has yet replicated this full morphology in a clinically viable construct - PMC.
Hydrogel Scaffold Approaches
A UK-based research team reported in April 2025 that they had developed a hydrogel scaffold that supports interactions between odontogenic (tooth-forming) cells. The scaffold provides structural guidance while the cells organize themselves into tooth-like structures. Early results show promising cell organization, but the constructs do not yet replicate the full morphology or mechanical function of natural teeth.
Peptide-Based Enamel Repair
Several groups are working on protein-mimicking peptides that can repair early-stage enamel decay. These peptides bind to damaged enamel surfaces and template the deposition of new hydroxyapatite crystals, effectively patching small cavities at the molecular level. While promising for cavity prevention, this approach does not regrow whole teeth. It is a repair mechanism, not a regeneration mechanism.
Gene Therapy Approaches
Early-stage research is exploring CRISPR-based gene editing to activate dormant dental genes directly. The theoretical advantage is precision: rather than blocking a suppressor protein systemically, you could activate specific tooth-development genes at specific sites. The practical challenges are enormous: delivery vectors for gene therapy to jaw tissue are undeveloped, regulatory barriers for gene editing in humans remain formidable, and the safety profile of dental gene therapy is completely unknown - PMC.
Other groups are exploring neural crest cell manipulation, targeting the embryonic cell population from which all dental tissues derive. MSX2 gene suppression has shown potential for cartilage regeneration in jaw tissue, but this work is very early stage.
Why Anti-USAG-1 Leads
The reason TRG-035 is years ahead of every competing approach comes down to a single structural advantage: it uses the body's existing machinery. Rather than trying to engineer teeth from scratch (stem cells, scaffolds, gene editing), it removes a molecular brake on a process the body already knows how to execute. The developmental program for tooth formation is already coded into the genome. The progenitor cells are already present in the gum tissue. The signaling pathways are already wired. The only missing element is permission.
This is why the approach works across species (mice, ferrets, dogs) without modification. The USAG-1 suppression mechanism is conserved across mammals because the tooth development program it suppresses is conserved. The antibody is not fighting biology. It is unlocking biology.
Every other approach requires building something new: a scaffold, a cell construct, a genetic modification. TRG-035 requires removing something old: a suppressor protein. In biological systems, subtraction is almost always simpler, safer, and more reliable than addition.
The regulatory pathway reflects this distinction. Monoclonal antibodies are among the best-understood drug modalities in modern pharmacology. The FDA, EMA, and PMDA all have well-established frameworks for evaluating antibody therapeutics, including clear guidelines for immunogenicity testing, pharmacokinetic characterization, and manufacturing quality control. Novel approaches like gene therapy, stem cell transplantation, and bioengineered scaffolds face much more complex regulatory pathways because the frameworks for evaluating their safety and efficacy are still evolving.
This regulatory advantage compounds over time. Even if a stem cell approach eventually proves more effective than TRG-035 for certain patients, the antibody will likely reach the market years earlier simply because the regulatory path is better defined. First-mover advantage in regenerative dentistry could establish TRG-035 as the standard of care before competing approaches complete their first human trials.
The intellectual property landscape also favors Toregem. The company holds patents on the specific anti-USAG-1 antibody (clone #37), the selective BMP-blocking mechanism, and the therapeutic application for tooth regeneration. Any competitor attempting to develop a different anti-USAG-1 antibody would need to either license Toregem's IP or demonstrate that their antibody has a sufficiently different mechanism of action. Given that the selectivity of clone #37 (BMP-blocking without Wnt-blocking) appears to be essential for safety, working around these patents without compromising the drug's therapeutic profile would be extremely difficult.
The landscape is not even close. Only one approach has reached human trials. Only one has consistent cross-species evidence. Only one has orphan drug designation, FDA engagement, and a commercial manufacturing partner.
11. The Skepticism: What Could Go Wrong
Any article about a breakthrough drug that does not address the skepticism is doing the reader a disservice. TRG-035 has genuine scientific merit, but it also faces genuine obstacles, and several aspects of the public conversation around it have been oversold.
The Animal-to-Human Translation Gap
The most fundamental uncertainty is whether results in mice and ferrets will translate to humans. Drug development is littered with therapies that worked brilliantly in animals and failed in people. The ferret experiments required five times the antibody concentration used in mice, three separate administrations instead of one, and immunosuppression to prevent rejection. This escalating dosage pattern raises questions about what concentration will be needed in humans and whether it can be achieved safely.
Off-Target Effects
USAG-1 is not expressed exclusively in dental tissue. It is also present in kidney, bone, and gingiva. Blocking USAG-1 in these tissues could affect BMP and Wnt signaling in unpredictable ways. The selective BMP-only blockade of antibody #37 mitigates this risk, but long-term safety data in humans does not yet exist. The Phase I trial is specifically designed to characterize these off-target effects, and the results will determine whether the drug can proceed.
The Tooth Bud Requirement
This is perhaps the most commonly misunderstood limitation. TRG-035 does not create tooth buds from nothing. It activates dormant, pre-existing third-dentition buds that are already embedded in the jaw. If a patient does not have residual tooth buds at the site of a missing tooth, the drug will not work at that site.
Snopes fact-checked the tooth regeneration claims and rated them as true, but emphasized that "specific conditions need to be met for the drug to regrow teeth; it might not spontaneously grow new teeth in just any person who takes it" - Snopes. The presence, location, and viability of dormant tooth buds likely varies between individuals and across different positions in the jaw. Some people may have abundant residual buds; others may have few or none.
Uncontrolled Growth Risks
In the animal studies, some treated animals developed fused mandibular molars or teeth in unexpected positions. Stimulating tooth formation pathways could potentially lead to unintended tissue growth, malformed dental structures, or teeth that erupt in locations where they interfere with existing teeth or jaw function. The dose-response relationship observed in mice (higher doses produce more reliable results but also more variability in outcomes) suggests a narrow therapeutic window that will need to be precisely calibrated for humans.
Media Overselling
Multiple dental researchers have noted that "communication about dental regeneration is extremely oversold in the press." Headlines suggesting that dentures will be "extinct" by 2030 dramatically overstate the near-term impact. The 2030 target date is for initial commercialization for the orphan indication (congenital anodontia in children). Broad availability for age-related tooth loss in adults would require additional years of clinical trials covering that specific population.
The drug is genuinely exciting and the science is sound, but it is in Phase I. Historically, approximately 90% of drugs that enter Phase I trials never reach the market. The failure rate is not because Phase I drugs are bad science. It is because human biology is complex, manufacturing at scale is hard, and regulatory requirements are stringent. Treating this as a certainty rather than a promising hypothesis is premature.
Developmental Safety Signals
In the Science Advances study, crosses between USAG-1 knockout and MSX1 knockout mice produced offspring that "were not born or did not survive" at rates suggesting developmental toxicity. While a therapeutic antibody (temporary, targeted) is fundamentally different from a genetic knockout (permanent, systemic), these observations cannot be entirely dismissed. Any application in pregnant women or very young children will require extraordinarily careful safety evaluation.
The Delivery Optimization Problem
Even beyond these biological unknowns, there is a practical engineering challenge that has received less attention in the popular press. Delivering a monoclonal antibody to a specific site in the jaw with sufficient concentration to activate local tooth buds while minimizing systemic exposure is not a solved problem.
Current monoclonal antibody therapies are typically administered intravenously (systemic), subcutaneously (semi-local), or intramuscularly. None of these routes are ideal for a dental application where you want high local concentration in the gum tissue at a specific tooth site. The Phase I trial uses direct gingival injection, which is conceptually simple but raises questions about antibody distribution within the tissue, clearance rates from the injection site, and whether a single injection provides sustained enough exposure for tooth bud activation.
The ferret experiments hint at this challenge. Where mice (small jaw, thin tissue) responded to a single systemic injection, ferrets (larger jaw, denser tissue) required three injections plus immunosuppression. Humans have even larger jaws and denser tissue. Optimizing the delivery to achieve the right concentration at the right site for the right duration is an engineering problem that sits at the intersection of pharmacology, materials science, and dental anatomy.
Future iterations may require sustained-release formulations (hydrogel depots that slowly release the antibody over weeks), targeted nanoparticle delivery (encapsulating the antibody in particles that preferentially bind to periodontal tissue), or multiple injection protocols calibrated to individual patient anatomy. None of these are insurmountable, but they add complexity to the commercialization pathway.
The Patient Selection Challenge
Perhaps the most practically important question for eventual broad adoption: how do you determine which patients have viable dormant tooth buds at specific jaw positions? Current dental imaging (panoramic X-rays, cone-beam CT scans) can detect fully formed supernumerary teeth, but the dormant third-dentition buds that TRG-035 aims to activate are microscopic epithelial structures. They are not visible on standard imaging.
This means that, at least initially, treatment would involve a degree of uncertainty. A patient missing a molar could receive the injection without knowing whether a dormant bud exists at that site. If it does, a tooth grows. If it does not, nothing happens (except the cost of the treatment and the time waiting for a result). Developing diagnostic tools to pre-screen for dormant tooth buds (perhaps using high-resolution MRI, molecular markers in gingival biopsies, or genetic predisposition testing) would significantly improve the value proposition by ensuring that only patients with viable buds receive treatment.
The honest assessment is that TRG-035 is the most promising tooth regeneration therapy ever developed, with the strongest preclinical evidence and the most advanced clinical program. It is also a Phase I drug with no human efficacy data, significant unknowns about off-target effects, and a patient-selection challenge (dormant tooth buds) that may limit its applicability. Both of these things are true simultaneously.
12. Where AI Meets Regenerative Dentistry
The intersection of artificial intelligence and regenerative medicine is one of the most consequential developments in modern healthcare, and tooth regeneration is a microcosm of this broader trend. AI is accelerating every stage of the drug development pipeline, from target identification to clinical trial design to manufacturing optimization.
In the specific case of tooth regeneration, computational protein modeling was instrumental in characterizing the binding surfaces of USAG-1 and designing antibodies with selective epitope targeting. The ability to predict protein-protein interactions computationally (rather than relying solely on experimental screening) compressed the timeline for identifying clone #37's selective BMP-blocking mechanism.
More broadly, AI-driven drug discovery platforms are reshaping how rare disease therapies reach patients. For conditions like congenital anodontia (prevalence 0.1-0.5%), traditional drug development economics are challenging: the patient population is small, the clinical trial recruitment is difficult, and the revenue potential is limited. AI helps overcome these barriers by reducing the cost and time of target validation, predicting patient populations, optimizing trial design, and accelerating regulatory submissions.
Google DeepMind's AI systems, including its clinical AI research, have demonstrated how machine learning can assist in everything from protein structure prediction (AlphaFold) to clinical decision-making. Our coverage of DeepMind's AI co-clinician explores how these systems are being deployed in clinical settings where treatment decisions depend on complex biological data, exactly the kind of context where tooth regeneration therapy will eventually need to be personalized per patient.
The broader picture of how AI is transforming scientific discovery is something we have documented extensively. Our guide to AI for scientific discovery covers the methodologies that are compressing decades of laboratory work into years, from automated hypothesis generation to robotic experimentation.
For life sciences specifically, the convergence of large language models with biological data is creating entirely new research paradigms. OpenAI's biology-focused models and similar tools from other AI labs are being applied to protein engineering, drug interaction prediction, and clinical trial optimization. Our analysis of AI in life sciences covers this landscape in depth.
Platforms like O-mega are part of this convergence, providing AI agent infrastructure that can automate research workflows, monitor clinical trial databases, and synthesize findings across thousands of papers, the kind of capability that accelerates the pace at which breakthroughs like TRG-035 move from laboratory to clinic.
The pattern is clear: biological intelligence (understanding how the body's own systems work) and artificial intelligence (processing vast datasets to find patterns humans cannot see) are becoming complementary tools. Tooth regeneration is a case study in what happens when deep biological knowledge meets modern computational methods. The result is a therapy that would have been science fiction 20 years ago, now in human trials.
The future convergence is even more striking. As tooth regeneration moves toward commercialization, AI will likely play a role in patient selection (predicting which patients have viable dormant tooth buds based on genetic and imaging data), treatment optimization (determining optimal antibody dosing based on individual jaw anatomy and tissue density), and outcome monitoring (tracking tooth development through serial imaging with automated analysis). The same AI infrastructure that is transforming how we build software agents and automate enterprise workflows, as we cover extensively across our articles on building AI agents, will be applied to biological systems with equal force.
The structural parallel between biological and digital automation is worth noting. In both domains, the most powerful interventions are not those that build entirely new systems from scratch, but those that unlock latent capabilities already present in the existing infrastructure. Just as the most effective AI agents are those that leverage existing tools and workflows rather than replacing them entirely, the most promising regenerative therapies are those that activate the body's existing developmental programs rather than engineering replacement tissues from scratch. TRG-035 is a biological "agent" that removes a suppressor and lets the body do what it already knows how to do.
13. What This Means for the Future of Aging
Tooth loss has been treated as an inevitable consequence of aging for all of recorded human history. Every civilization has developed some form of prosthetic tooth replacement: Etruscans used gold bridgework, Mayans implanted carved stones, 18th-century Europeans wore dentures made from hippopotamus ivory. The underlying assumption, that lost teeth are gone forever, has been a fixed constant of the human condition.
TRG-035 challenges that assumption at the biological level. If the body can be triggered to grow new teeth from dormant buds, then tooth loss is not irreversible. It is a condition that can be treated. The distinction matters enormously for how we think about aging.
Teeth as a Canary for Regenerative Medicine
Teeth are one of the few organs that humans cannot naturally regenerate. Skin heals. Bones knit. The liver can regrow from a fragment. But teeth, once lost, are gone. This makes tooth regeneration a bellwether: if we can crack the code for teeth, the principles may extend to other non-regenerating tissues.
The mechanism behind TRG-035 (removing a suppressor protein to reactivate a dormant developmental program) is conceptually applicable beyond dentistry. Many tissues contain progenitor cells that are held in quiescence by inhibitory signals. Hair follicles, cartilage, cardiac muscle, and neural tissue all have varying degrees of latent regenerative capacity that is suppressed by specific molecular mechanisms. The question is whether the same "remove the brake" strategy can be applied elsewhere.
This is not to say that blocking USAG-1 will regrow hearts or brains. The biology is tissue-specific, and each organ has different developmental programs and different suppression mechanisms. But the conceptual framework, that the body's regenerative capacity is not absent but suppressed, and that targeted removal of specific suppressors can unlock that capacity, is a paradigm that extends well beyond teeth.
The Longevity Implications
Japan's situation makes the longevity implications particularly vivid. A country where nearly 30% of the population is over 65, where the average lifespan exceeds 84 years, and where tooth loss correlates with cognitive decline and mortality risk, has an enormous stake in any therapy that can maintain dental function into advanced age.
The research linking tooth loss to cognitive decline is not speculative. Multiple large-scale studies have found that individuals who retain more natural teeth show slower rates of cognitive decline and lower incidence of dementia. The proposed mechanisms include reduced masticatory (chewing) stimulation of the brain, chronic inflammation from periodontal disease, and nutritional deficiency from inability to eat diverse foods. If tooth regeneration can maintain dental function, the downstream effects on brain health and nutritional status could extend healthy lifespan.
This connects to the broader movement in longevity science, where the focus is shifting from extending lifespan (living longer) to extending healthspan (living longer in good health). Tooth loss is one of the most common quality-of-life degradations in aging, affecting eating, speaking, social confidence, and nutritional status. A drug that addresses it targets healthspan directly.
What the 2030 Timeline Really Means
If Toregem's development timeline holds, the first commercially available tooth regeneration drug could be on the market by 2030. Initial availability will be restricted to the orphan indication (congenital anodontia in children), but expansion to broader populations would follow.
The timeline matters because it intersects with several other trends in regenerative medicine and biotechnology. By 2030, GLP-1 receptor agonists will have reshaped the obesity treatment landscape. Gene therapies for rare diseases will be proliferating. Senolytics (drugs that clear senescent cells) may be in late-stage trials. Tooth regeneration would enter a market where the public is increasingly accustomed to biological interventions that were previously unimaginable.
The dentist of the future may not pull teeth. They may prescribe a drug that grows new ones.
Parallels to Other "Impossible" Breakthroughs
The trajectory of tooth regeneration mirrors several other medical breakthroughs that were considered impossible until they suddenly were not. GLP-1 receptor agonists (semaglutide, tirzepatide) were initially developed as diabetes drugs, and the idea that a weekly injection could cause sustained 15-20% body weight loss was met with deep skepticism until Phase III data proved otherwise. Now they represent the fastest-growing drug class in pharmaceutical history.
Similarly, mRNA vaccines were considered a fringe technology for decades, with most pharmaceutical companies betting on traditional viral vector or protein subunit approaches. The COVID-19 pandemic forced rapid deployment, and within 18 months, mRNA went from "experimental" to "standard of care for pandemic response." The technology now underpins cancer vaccine research, gene therapy, and protein replacement therapy programs across dozens of indications.
The pattern is consistent: a technology that experts have been quietly developing for years or decades reaches a critical proof-of-concept threshold, and what was considered speculative suddenly becomes inevitable. The gap between "this might work in theory" and "this works in humans" is enormous. But once the second threshold is crossed (which is what TRG-035's Phase I trial represents), the commercialization timeline compresses dramatically because the remaining steps (dose optimization, indication expansion, manufacturing scale-up) are execution problems, not discovery problems.
Tooth regeneration is approaching that same inflection point. The basic science has been established for nearly two decades. The mechanism is understood. The drug candidate is identified. The manufacturing partner is onboard. The regulatory pathway is defined. What remains is execution, and the first human data that will determine whether execution proceeds or stops.
The Investment Angle
For the health-tech investment community, tooth regeneration represents a category worth watching. The addressable market is enormous (billions in implants and dentures), the competitive landscape is sparse (only one drug in human trials), and the regulatory pathway is de-risked through orphan drug designation. Toregem's $10 million Series B is modest by pharma standards, suggesting significant upside if Phase I results are positive.
As we have covered in our analysis of early-stage AI investors, the most consequential investments often come at inflection points where scientific proof-of-concept meets commercial feasibility. Tooth regeneration appears to be at exactly that inflection point.
The health-tech startup landscape, including companies like Cleerly (which raised $106M for AI-powered heart health detection, as we covered here), demonstrates that investors are willing to make large bets on technologies that fundamentally change how medical conditions are treated rather than incrementally improving existing treatments.
The bottom line is this. Humans have carried the biological machinery for a third set of teeth inside their jaws for their entire evolutionary history. A protein called USAG-1 kept that machinery switched off. A team in Japan figured out how to switch it back on. They tested it in mice, ferrets, and dogs. It worked in all of them. Now they are testing it in humans. The science is real. The clinical trial is real. The timeline is aggressive but achievable.
Whether TRG-035 succeeds or fails will be determined by the Phase I data. But regardless of the outcome for this specific drug, the principle it demonstrates, that regeneration is not a capability the body lacks but a capability the body suppresses, will reshape how we think about aging, organ loss, and the boundaries of human biology for decades to come.
The deeper lesson of TRG-035, whether it succeeds or not as a specific product, is that we have been too quick to accept biological limitations as permanent. For centuries, we assumed tooth loss was irreversible because we never found the switch that controlled it. The switch was there all along. A protein in the gums, suppressing a developmental program that the body has been carrying since before birth, waiting for permission to execute.
How many other "irreversible" conditions are actually reversible, held in check by molecular suppressors we have not yet identified? That question, more than any single drug, is what makes this moment in regenerative medicine so consequential. Every organ, every tissue, every biological system that we currently treat as permanently damaged may contain dormant regenerative programs waiting for their own USAG-1 to be switched off.
The era of irreversible tooth loss may be ending. And with it, a small but significant piece of what it means to grow old.
This guide reflects the state of tooth regeneration research as of May 2026. Clinical trial results, regulatory decisions, and commercialization timelines are subject to change. Verify current developments before making health or investment decisions.